Potential candidates for the new hepatitis C drugs will need to consider the drugs’ price, which will be added to the already steep cost of interferon and ribavirin.
Activists call for people with bleeding disorders, who are typically excluded from clinical trials for hepatitis C, to be given emergency access to promising new drugs being studied.
Liver transplants can have good outcomes if patients know what to ask their hematologist, when to confer with a hepatologist and when to be listed in a national liver transplant database.
For people with hemophilia and hepatitis C, the question is whether new techniques are viable alternatives to liver biopsy, considered the gold standard for diagnosing the extent of liver disease.
